Levels of disialogangliosides in sera of melanoma patients monitored by sensitive thinlayer chromatography and immunostaining

Ben Ami Sela, Dimitrios Iliopoulos, Dupont Guerry, Dorothee Herlyn*, Hilary Koprowski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Levels of GD2, GD3, and 9-O-acetyl GD3 were monitored in sera of patients with melanoma and healthy adults with two monoclonal antibodies that specifically detect these gangliosides. By direct measurement of radioactivity in the im-munolabeled chromatogram, GD2 could be detected in normal sera at 2 ng/mL. Serum levels of GD2 and GD3 were increased approximately sixfold and fivefold, respectively, in patients with disseminated melanoma, compared with those of healthy adults. The acetylated derivative of GD3, which is highly specific for melanoma cells, was not detected in serum. This sensitive assay allows the quantitation of tumor-associated gangliosides that are circulating in sera of melanoma patients. [J Natl Cancer Inst 81: 1489-1492, 1989]

Original languageEnglish
Pages (from-to)1489-1492
Number of pages4
JournalJournal of the National Cancer Institute
Volume81
Issue number19
DOIs
StatePublished - 4 Apr 1989

Fingerprint

Dive into the research topics of 'Levels of disialogangliosides in sera of melanoma patients monitored by sensitive thinlayer chromatography and immunostaining'. Together they form a unique fingerprint.

Cite this